

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



160 Health International Limited

健康 160 国际有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2656)

POSITIVE PROFIT ALERT

This announcement is made by 160 Health International Limited (the “**Company**”, together with its subsidiaries and consolidated affiliated entities, the “**Group**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board (the “**Board**”) of directors (the “**Directors**”) of the Company wishes to inform the shareholders and potential investors of the Company that, based on the preliminary assessment of the unaudited consolidated management accounts of the Group for the year ended December 31, 2025 (the “**Year**”) and the information currently available to the Company, the Group expects to record an adjusted net profit (non-IFRS measure) ranging from RMB3.0 million to RMB5.0 million for the Year, as compared to an adjusted net loss (non-IFRS measure) of RMB31.5 million for the year ended December 31, 2024 (the “**Corresponding Period Last Year**”). This marks the first time the Group has reported a full-year profit in terms of adjusted net profit (non-IFRS measure).

The turnaround to the adjusted net profit (non-IFRS measure) for the Year were primarily attributable to the combined effect of the following: (i) the year-on-year growth in revenue, which led to a slight increase in gross profit; and (ii) the refined management and continuous enhancement of operational efficiency, led to the significant decrease in total operating expenses (including selling and marketing, research and development, and administrative expenses) for the Year.

The Board wishes to emphasize that “adjusted net profit” is not defined under IFRS. The Group defines it as the profit for the year adjusted by adding back (i) share-based compensation expenses and (ii) listing expenses (collectively, the “**Adjusted Items**”). Among them, share-based compensation expenses are non-cash items that do not affect the cash flow and core business operations during the period. The Board is of the view that adjusted net profit eliminates the potential impact of the Adjusted Items (which are non-operational in nature and may not reflect the Group’s actual operational performance), thereby providing useful information to potential investors and others in understanding and evaluating the Group’s results of operations.

The information contained in this announcement is only based on the preliminary assessment of the Group’s unaudited consolidated management accounts for the Year and other information currently available to the Company. Such information has not been audited or reviewed by the independent auditor of the Company, nor has it been reviewed by the audit committee of the Company, and is subject to finalization and potential adjustments upon further review. The actual results of the Group for the Year may differ from the information contained in this announcement. Further details of the Group’s financial results and performance will be disclosed in the Group’s annual results announcement for 2025, which is expected to be published by the end of March 2026.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
160 Health International Limited
Mr. LUO Ningzheng
*Chairman of the Board, Executive Director
and Chief Executive Officer*

Hong Kong, March 17, 2026

As of the date of this announcement, the Board comprises (i) Mr. LUO Ningzheng, Mr. JI Cuilin, Mr. HUANG Lang and Mr. WANG Lifa as executive Directors; (ii) Mr. LIU Haibin and Ms. SUN Meng as non-executive Directors; and (iii) Mr. WANG Huan, Dr. XU Weiguo and Dr. FAN Ming as independent non-executive Directors.